Tempus AI Unveils $200M Deals to Build Oncology's Largest AI Model
Summary
Tempus AI unveils groundbreaking $200M deals with AstraZeneca and Pathos AI to build the largest AI model in oncology, harnessing multimodal data to drive biological insights, drug target discovery, and therapeutic development for cancer patients.
Key Points
- Tempus AI announced multi-year strategic collaborations with AstraZeneca and Pathos AI to develop the largest multimodal foundation model in oncology
- The agreements include $200 million in data licensing and model development fees to Tempus AI
- The foundation model aims to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the oncology community